Y Shahin1, J R Cockcroft, I C Chetter. 1. Academic Vascular Surgical Unit, Hull York Medical School and University of Hull, Hull, UK. yousef.shahin@yahoo.co.uk
Abstract
BACKGROUND: The aim was to investigate the effect of ramipril on clinical parameters in patients with peripheral arterial disease. METHODS:Patients with intermittent claudication were randomized to receive ramipril or placebo for 24 weeks in a double-blind study. Outcome measures were walking distance, arterial stiffness measurement and quality of life (QoL). RESULTS:A total of 33 patients were included (25 men; mean(s.d.) age 64.6(7.8) years); 14 receivedramipril and 19 placebo. After 24 weeks, ramipril improved maximum treadmill walking distance by an adjusted mean (95 per cent confidence interval, c.i.) of 131 (62 to 199) m (P = 0·001), improved treadmill intermittent claudication distance by 122 (56 to 188) m (P = 0.001) and improved patient-reported walking distance by 159 (66 to 313) m (P = 0.043) compared with placebo. Ramipril reduced carotid femoral pulse wave velocity by -1.47 (95 per cent c.i. -2.40 to -0.57) m/s compared with placebo (P = 0.002). Resting ankle : brachial pressure index (ABPI) improved slightly in both ramipril and placebo groups (0.02 (95 per cent c.i. -0.08 to 0.11) versus 0.03 (-0.05 to 0.10); P = 0.830). Ramipril had a slight, non-significant effect on QoL physical domains compared with placebo. CONCLUSION:Ramipril improved walking distance in patients with claudication; however, this improvement was not related to improved ABPI but might have been due to ramipril reducing arterial stiffness. REGISTRATION NUMBER: NCT01037530 (http://www.clinicaltrials.gov).
RCT Entities:
BACKGROUND: The aim was to investigate the effect of ramipril on clinical parameters in patients with peripheral arterial disease. METHODS:Patients with intermittent claudication were randomized to receive ramipril or placebo for 24 weeks in a double-blind study. Outcome measures were walking distance, arterial stiffness measurement and quality of life (QoL). RESULTS: A total of 33 patients were included (25 men; mean(s.d.) age 64.6(7.8) years); 14 received ramipril and 19 placebo. After 24 weeks, ramipril improved maximum treadmill walking distance by an adjusted mean (95 per cent confidence interval, c.i.) of 131 (62 to 199) m (P = 0·001), improved treadmill intermittent claudication distance by 122 (56 to 188) m (P = 0.001) and improved patient-reported walking distance by 159 (66 to 313) m (P = 0.043) compared with placebo. Ramipril reduced carotid femoral pulse wave velocity by -1.47 (95 per cent c.i. -2.40 to -0.57) m/s compared with placebo (P = 0.002). Resting ankle : brachial pressure index (ABPI) improved slightly in both ramipril and placebo groups (0.02 (95 per cent c.i. -0.08 to 0.11) versus 0.03 (-0.05 to 0.10); P = 0.830). Ramipril had a slight, non-significant effect on QoL physical domains compared with placebo. CONCLUSION:Ramipril improved walking distance in patients with claudication; however, this improvement was not related to improved ABPI but might have been due to ramipril reducing arterial stiffness. REGISTRATION NUMBER: NCT01037530 (http://www.clinicaltrials.gov).
Authors: Mary M McDermott; Lydia Bazzano; Charlotte A Peterson; Robert Sufit; Luigi Ferrucci; Kathryn Domanchuk; Lihui Zhao; Tamar S Polonsky; Dongxue Zhang; Donald Lloyd-Jones; Christiaan Leeuwenburgh; Jack M Guralnik; Melina R Kibbe; Kate Kosmac; Michael H Criqui; Lu Tian Journal: JAMA Date: 2022-10-04 Impact factor: 157.335
Authors: Thomas C F Bodewes; Jeremy D Darling; Thomas F X O'Donnell; Sarah E Deery; Katie E Shean; Murray A Mittleman; Frans L Moll; Marc L Schermerhorn Journal: J Vasc Surg Date: 2017-11-02 Impact factor: 4.268
Authors: Diana Thomas Manapurathe; Smriti Murali Krishna; Brittany Dewdney; Joseph Vaughan Moxon; Erik Biros; Jonathan Golledge Journal: PLoS One Date: 2017-06-02 Impact factor: 3.240